Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × OTHER × Castrate Resistant Prostate Cancer × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 77 Neoplasms 67 Carcinoma, Hepatocellular 47 Prostatic Neoplasms 44 Colorectal Neoplasms 44 Leukemia, Myeloid, Acute 37 Stomach Neoplasms 33 Carcinoma, Non-Small-Cell Lung 33 Precursor Cell Lymphoblastic Leukemia-Lymphoma 31 Neoplasm Metastasis 26 Pancreatic Neoplasms 25 Lung Neoplasms 21 Rectal Neoplasms 20 Multiple Myeloma 20 Hematologic Neoplasms 18 Recurrence 17 Lymphoma 16 Colonic Neoplasms 16 Leukemia 15 Polycystic Ovary Syndrome 14 Esophageal Neoplasms 13 Head and Neck Neoplasms 12 Myelodysplastic Syndromes 11 Motor Activity 11 Fatigue 11 Liver Neoplasms 10 Depression 10 Brain Neoplasms 10 Glioblastoma 9 Esophageal Squamous Cell Carcinoma 9

Interventions

Melphalan 1 Lenograstim 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01907009 2023-04-19

MEL-CAP

Barts & The London NHS Trust

Phase 2/3 Terminated

Castrate Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡